Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities

Prior treatment

• Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma. Participants with a history of gestational diabetes are eligible to participate in this trial. Have a self-reported change in body weight >5 kg (11 pounds) within 3 months prior to screening.
  • 2.Have a history of acute or chronic pancreatitis any time prior to screening.

Other illness

• Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2. "

• 1-Be able to provide signed informed consent and comply with study requirements.
• 2-Be ≥18 years old (or legal age of consent locally).
• 3-Have: BMI ≥30 kg/m², or 4-BMI ≥27 kg/m² with at least one weight-related comorbidity such as: cardiovascular disease, hypertension, dyslipidemia, or obstructive sleep apnea.
• 5-Have at least one prior unsuccessful dietary weight-loss attempt.
• 6-Not be pregnant or breastfeeding; contraception requirements apply per local regulations.